Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases

BACKGROUND: In the INBUILD trial in patients with chronic fibrosing interstitial lung diseases (ILDs) and a progressive phenotype, nintedanib reduced the rate of ILD progression with adverse events that were manageable for most patients. We investigated the potential impact of immunomodulatory thera...

Descripción completa

Detalles Bibliográficos
Autores principales: Cottin, Vincent, Richeldi, Luca, Rosas, Ivan, Otaola, Maria, Song, Jin Woo, Tomassetti, Sara, Wijsenbeek, Marlies, Schmitz, Manuela, Coeck, Carl, Stowasser, Susanne, Schlenker-Herceg, Rozsa, Kolb, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7962343/
https://www.ncbi.nlm.nih.gov/pubmed/33726766
http://dx.doi.org/10.1186/s12931-021-01668-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7962343/
https://www.ncbi.nlm.nih.gov/pubmed/33726766
http://dx.doi.org/10.1186/s12931-021-01668-1

Ejemplares similares